MDR Annex XVI Classification: GIF PL Compliance Gaps in 2026

The Annex XVI Activation Date That Keeps Generating Compliance Gaps

Commission Implementing Regulation (EU) 2022/2346 set 22 June 2023 as the date from which the common specifications (CS) became applicable to Annex XVI products — those without an intended medical purpose listed in Regulation (EU) 2017/745. That date passed. Yet the compliance surface it created for manufacturers placing non-medical-purpose devices on the Polish market continues to generate classification disputes, borderline questions, and conformity assessment gaps that surface during GIF inspections. The problem is not the regulation itself — the text is clear enough. The problem is that most product portfolios contain assets whose regulatory status under Article 1(2) of the MDR has never been formally resolved at the national level, and whose qualification files contain assumptions carried forward from Council Directive 93/42/EEC rather than from the current MDR framework.

Qualification Before Classification: A Step That Is Frequently Compressed

MDCG 2023-5 makes the sequencing explicit: qualification of a product as an Annex XVI device precedes classification under Annex VIII classification rules. These are two distinct regulatory determinations — one establishes whether the MDR applies at all; the other establishes the conformity assessment route. In practice, manufacturers commonly compress these steps, proceeding directly to classification under Rule 1 or Rule 2 of Annex VIII without formally resolving the threshold question of whether the product falls within the scope descriptions of the Annex XVI groups. Where the product’s description partially matches an Annex XVI group but includes features that arguably place it outside the CS scope sections, the qualification gap may only become visible when a notified body or GIF examines the technical file under the MDR framework — at which point remediation requires reopening the conformity assessment procedure.

The Manual on Borderline and Classification for Medical Devices, Version 5 of April 2026, documents the agreements reached under the Helsinki Procedure across Member State competent authorities, and it is one of the primary reference tools GIF inspectors and Polish competent authority reviewers apply when resolving borderline cases. Version 5 is the current operative version. Manufacturers whose borderline analysis was conducted against earlier versions — or, more critically, against the predecessor Manual issued under the now-repealed Directive 93/42/EEC — carry a structural documentation risk. The MDCG Working Group on Borderline and Classification noted that the previous Manual under the Directives is kept available for reference only while MDD-marked devices remain on the market; it is not an analytical basis for new Annex XVI qualification decisions.

Where Equivalence Claims Create a Data Integrity Problem

MDCG 2023-6 addresses a specific compliance scenario that is more common in Annex XVI portfolios than it might appear: the use of clinical data from an equivalent device to satisfy clinical evaluation requirements under MDR Annex XIV Part A. For products without an intended medical purpose, this path is narrower than for medical devices. Commission Implementing Regulation (EU) 2022/2346, recital (11), establishes that in general it is not possible to demonstrate equivalence between a medical device and a product without an intended medical purpose. Where manufacturers have constructed their clinical evaluation by drawing on data from a device that straddles this boundary — a dual-purpose device for which the equivalence analysis applies only to the non-medical intended purpose — the clinical evaluation may carry a gap that is not visible in the document index but is embedded in the underlying data architecture.

This is where the compliance problem becomes, at its core, a data quality problem. Equivalence claims in technical files are rarely single documents — they are chains of cross-referenced clinical data, characteristic comparisons across technical, biological, and clinical dimensions, and assertions about shared intended purposes. When those chains are reconstructed from legacy MDD documentation rather than rebuilt against the MDR criteria in Annex XIV Part A Section 3, the internal consistency of the file degrades in ways that are not obvious from a document checklist review. MDCG 2023-6 clarifies exactly which elements of the clinical criterion apply to products without a medical purpose and which require reinterpretation — and a significant proportion of equivalence files in circulation were constructed before that clarification existed. Where GIF conducts a technical file audit under Article 1(2) of the MDR, a file built on a pre-2023 equivalence analysis may surface a clinical evaluation gap that the manufacturer did not anticipate.

Transitional Provisions: The Window That Narrowed Further in 2023

Regulation (EU) 2023/607 extended the MDR transitional provisions for certain categories of devices, and Commission Implementing Regulation (EU) 2023/1194 amended the CS transitional provisions further. For Annex XVI products, the Q&A document published by the European Commission in September 2023 clarifies the interaction between these instruments. A fixed 6-month implementation window ran from 22 December 2022 to 22 June 2023. Beyond that window, dedicated transitional provisions apply only to specific cases: where a notified body must be involved in the conformity assessment procedure, where the manufacturer intends to conduct a clinical investigation followed by notified body conformity assessment, or where the product was covered by a valid MDD certificate. For products that do not fall into these categories, the full MDR requirements under Regulation (EU) 2017/745 and the CS under Regulation (EU) 2022/2346 apply without transitional relief. Where a product’s status within these categories has not been formally documented, GIF may in practice interpret the absence of that documentation as evidence that the transitional provisions do not apply — and assess the product against the full current MDR standard.

Pharmacovigilance and Post-Market Obligations That Follow Classification

The compliance surface for Annex XVI products does not end at conformity assessment. Classification under Annex VIII of the MDR determines the post-market surveillance (PMS) intensity and the serious incident reporting obligations under the MDR’s vigilance framework. A product classified as Class IIa or above under Regulation (EU) 2017/745 carries periodic safety update report (PSUR) obligations on a defined cycle, and incident reports must flow through EUDAMED once the relevant modules are fully operational. For manufacturers entering the Polish market under GIF oversight, the EUDAMED registration requirement — including operator and device registration — is a parallel compliance obligation that sits alongside the GIF notification process. A pattern observed across technical file reviews in this category is that EUDAMED registration status and GIF market notification records are maintained independently, creating a data divergence that may be identified during cross-registry inspection preparation. Vestango’s automated monitoring pipeline, drawing on 55+ regulatory sources including EUDAMED actor and device records, is capable of detecting this divergence before it becomes visible to the competent authority.

GMP Signals from Outside the EU That Affect Polish Market Entry

The NMPA’s 2026 post-market vigilance framework for overseas medical device manufacturers, and China’s medical device GMP overhaul currently in transition, are relevant to Polish market strategy for a specific reason: manufacturers whose quality management systems are certified against ISO 13485 for non-EU markets may find that the QMS architecture does not map directly onto the requirements of Annex IX of the MDR — the conformity assessment route most commonly used for Class IIa and Class IIb products. Where a manufacturer has obtained a quality system certificate in a third-country framework and is seeking to extend market access to Poland under GIF oversight, the gap between the third-country QMS certification basis and the Annex IX requirements under Regulation (EU) 2017/745 may require a structured remediation step before notified body engagement. This is a pattern that is likely to increase in frequency as global manufacturers with existing China NMPA or Health Canada post-NOC quality certification seek EU/Polish market entry — the certification basis is different even where the quality principles overlap.

The Intelligence Architecture Behind a GIF-Ready Technical File

Resolving the compliance gaps described above requires more than a document checklist. It requires a structured intelligence product: a scored regulatory profile of the product that maps qualification status, classification basis, equivalence claim integrity, transitional provision applicability, EUDAMED registration state, and PMS tier — each dimension sourced from the relevant public registry or regulatory instrument and cross-validated. Vestango constructs this as a queryable dataset, not a consulting narrative. The qualification and classification assessment draws on the MDR Article 1(2) scope determination, the Annex VIII classification rules as interpreted in MDCG 2021-24 Rev.1 (April 2026), and the current borderline manual (Version 5, April 2026). The clinical evaluation gap analysis maps against MDCG 2023-5, MDCG 2023-6, and the CS under Regulation (EU) 2022/2346. EUDAMED registration status is queried directly from the public EUDAMED interface. Where GIF inspection records are accessible through the GIF public database, those records are incorporated into the scored profile. The output is a structured dataset across these dimensions — scored, verifiable, and sufficient for the manufacturer’s own regulatory team to draw independent conclusions about remediation priorities.

If your product portfolio includes Annex XVI assets whose qualification and classification files were last reviewed under the MDD framework, or whose equivalence claims predate the MDCG 2023-5 and MDCG 2023-6 guidance, or whose EUDAMED and GIF registration records have not been cross-validated, the compliance gap is identifiable before a GIF inspection opens — and that is the only moment at which remediation is fully within your control. Vestango can conduct an initial review and surface the first structured findings within 48 hours: an initial compliance gap analysis mapped to the specific MDR articles and MDCG guidance documents applicable to your product category, alongside the aggregated registry dataset — scored across EUDAMED registration status, classification tier, CS transitional provision applicability, and GIF notification records — that makes the findings verifiable rather than advisory. Contact Vestango.

The analysis in this article draws on publicly available regulatory data, published guidelines, and the accumulated experience of Vestango Life Sciences in EU and Polish regulatory affairs. It reflects patterns we observe — not universal conclusions. Every regulatory situation is product-specific, market-specific, and jurisdiction-specific. What applies to one portfolio may not apply to yours. If any of the issues raised here resonate with your situation, the right next step is a structured, case-specific conversation — not the application of general conclusions. With our founder Paweł Wojtaszczyk, Ph.D. Eng., we work at the intersection of data science and regulatory affairs, translating that combination into real market implementations. We solve problems and build companies operating in the life sciences market. Contact Vestango.